Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2023-05-24 Remuneration Information
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA - Share option grant
Remuneration Information Classification · 99% confidence The document announces the grant of share options to employees, including specific details about the number of options, exercise price, and the allocation to primary insiders (CEO, CFO, etc.). This type of transaction, involving personal share transactions by company directors and executives, directly falls under the definition of Director's Dealing (insider trades). Although it mentions the options were approved by the AGM, the core subject is the insider transaction itself. Therefore, the appropriate classification is DIRS.
2023-05-24 English
Photocure ASA - Share option grant
Remuneration Information Classification · 99% confidence The document is a short announcement from Photocure ASA regarding the granting of share options to employees, including specific allocations to primary insiders (CEO, CFO, etc.). This type of transaction, involving personal share transactions by directors and executives, falls directly under the definition of Director's Dealing (insider trades). Although it mentions remuneration guidelines, the core subject is the grant of options to insiders, making 'DIRS' the most appropriate classification over 'DEF 14A' (which is for comprehensive remuneration reports). The document is short and appears to be a direct regulatory disclosure, not an announcement of a larger report.
2023-05-24 English
Photocure ASA: Results for the first quarter of 2023
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive quarterly financial report for Photocure ASA for Q1 2023. It contains detailed financial statements (Income Statement), operational reviews, management commentary, and key performance indicators (KPIs). It is not an announcement of a report (RPA) or a simple earnings release (ER) because it provides extensive narrative analysis and detailed financial tables. It fits the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-10 Norwegian
Photocure ASA: Results for the first quarter of 2023
Investor Presentation Classification · 99% confidence The document is explicitly titled "Photocure ASA 1st Quarter 2023 Results" and contains detailed financial tables for Q1 '23 compared to Q1 '22, including consolidated income statements, segment performance, and operational highlights for the quarter. This structure is characteristic of a comprehensive quarterly financial report, which aligns with the definition of an Interim / Quarterly Report (IR). It is not merely an Earnings Release (ER) as it contains extensive segment breakdowns and detailed financial statements, nor is it the Annual Report (10-K) as it covers only the first quarter. Since it is a comprehensive report for a period shorter than a year, the correct classification is IR.
2023-05-10 Norwegian
Photocure ASA: Results for the first quarter of 2023
Earnings Release Classification · 98% confidence The document is titled "Photocure ASA: Results for the first quarter of 2023" and provides detailed financial metrics (revenues, EBITDA, EBIT) and operational highlights for Q1 2023. It discusses performance against guidance and reiterates the full-year outlook. This content structure is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it contains detailed financial figures and management commentary on the period's performance, it leans towards a comprehensive report rather than just a brief highlight announcement. However, the text explicitly mentions: "Please find the full financial report and presentation enclosed," and later, "The quarterly report and presentation will be published at 08:00 CEST...". This suggests the current document is the announcement *about* the release of the full report, which aligns with the definition of an Earnings Release (ER) which is the initial announcement of periodical financial results (key highlights only). Given the depth, it is a strong candidate for ER, but if a more comprehensive report exists (as implied by 'enclosed'), ER is the best fit for the announcement itself, as opposed to the full 'IR'. Since it provides the core results and guidance update, ER is the most appropriate classification for this announcement. Q1 2023
2023-05-10 Norwegian
Photocure ASA: Results for the first quarter of 2023
Earnings Release Classification · 100% confidence The document explicitly states it contains the "Results for the first quarter of 2023" for Photocure ASA, detailing key financial metrics like revenues (NOK 105.9 million) and EBITDA (minus NOK 1.2 million) for the period ending Q1 2023. This content structure—reporting period results, management commentary, and forward guidance—is characteristic of an Earnings Release (ER). Although it mentions the full financial report and presentation are enclosed/will be published, the primary content provided here is the summary announcement of the results, which fits the definition of an Earnings Release (ER). It is not the comprehensive 'Interim Report' (IR) itself, nor is it merely an announcement of the report's publication (RPA), as it contains the actual results summary. The document length (6836 chars) is substantial enough to contain the core results summary. Q1 2023
2023-05-10 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.